samedan logo
home > news > detailed info

B Medical Systems launches €15m factory extension in Luxembourg

B Medical Systems

B Medical Systems (BMS), a global leader in the medical cold chain industry and manufacturer of ultra-low freezers, vaccine refrigerators, freezers, and transport boxes has unveiled a €15m extension at its manufacturing facility in Hosingen, Luxembourg.

BMS launched the manufacturing facility in January 2021, which was attended by His Royal Highness Hereditary Grand Duke of Luxembourg, Prince Guillaume.

Just ten months on, BMS has unveiled a new €15m multi-phase expansion, which was part-funded by the Ministry of the Economy as part of the aid for an investment project to help combat the health crisis.

The 4,500m2 extension, which was constructed in six months, will help BMS double its production capacity for vaccine cold chain units while production of its ultra-low freezers is expected to increase five-fold. The new facililty includes assembly lines, end of testing lines, and packaging sections. A warehouse and office space will be added by the end of the year. It’s thought the expansion will create 150 jobs in the region.

Luc Provost, CEO of B Medical Systems said: “The global rollout of COVID-19 vaccines created an unprecedented demand for vaccine cold chain solutions and to cater to this global demand, we needed to expand our production facility. This multimillion euro expansion reflects our commitment to the world to ensure reliable medical cold chain solutions with the shortest lead times. Our aim is to make Luxembourg, a global leader in the end-to-end medical cold chain industry, and this facility takes us one step closer to realising this dream.”

The launch event also included a demonstration of the Refrigerated Vaccine Transport Vehicle (RVTV), jointly developed by BMS and Toyota Tsusho Corporation (TTC). This is the first-ever refrigerated vehicle in the world to obtain a WHO PQS prequalification which can be used for reliably transporting vaccines or any other specimens in a 2-8 °C temperature range.

B Medical Systems is a global leader in the medical cold chain industry. It manufactures ultra-low freezers, vaccine refrigerators, freezers, and transport boxes among many other products for storing and transporting vaccines and other temperature-sensitive specimens across the world.

Its ultra-low freezers, vaccine refrigerators/freezers, laboratory refrigerators/ freezers, and transport boxes can store and transport COVID-19 vaccines at various temperature profiles ranging from -80°C to 8°C. BMS has provided more than 70,000 cold chain units to 140+ countries for their effective COVID-19 immunization programs. B Medical Systems is also the exclusive supplier of Luxembourg’s COVID-19 vaccine cold chain solution.

B Medical Systems also manufactures blood management solutions including blood bank refrigerators, plasma freezers, plasma shock freezers used by the clinical and blood /transfusion sectors across the world. The company has 40+ years of experience in providing reliable cold chain solutions and works with humanitarian organisations including UNICEF, the Red Cross, ministries of health, hospitals, research institutes, pharmaceutical companies across the world. The company has regional subsidiaries in the United States and India.
phone +352 92 07 31 1
email 17, op der Hei L-9809 Hosingen
Print this page
Send to a friend
News and Press Releases

Winners of the 2021 CPhI Pharma Awards have now been announced

Milan, 10 November 2021: CPhI Worldwide announces the winners of the 18th edition of the CPhI Pharma Awards, hosted live in Milan, with winners spanning some 10 distinct categories. The Awards seek to recognise ‘Excellence in Pharma’ , assessing entries from the industry leading companies and individuals.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement